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QALYs (1.5423) in comparison with adalimumab (1.5048), infliximab (1.4299) and
tocilizumab (1.4955). Etanercept appeared as the least expensive alternative at both
ACR20 ($69,410.32) and ACR70 ($176,178.43). The highest costs were obtained by
infliximab, ACR20 ($139,291.80) and ACR70 ($612,236.06). Cost-effectiveness
analyses exhibited etanercept as the dominant strategy. Acceptability curves
showed that at the willingness-to-pay of US$8,000/QALY, the probability that et-
anercept is cost-effective met 100%. PSA results support the robustness of these
findings.CONCLUSIONS: Etanercept is the most cost-effective alternative for treat-
ing RA against other anti-TNF and IL-6 blockers. According to 3 GDP per capita
($5,200; 2010) threshold of Guatemala, etanercept is a cost-effective treatment for
RA.
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OBJECTIVES: Determine the cost-effectiveness of abatacept or tocilizumab in pa-
tients with rheumatoid arthritis (RA) with inadequate response to methotrexate
(IR-MTX) in Colombia.METHODS:A patient-level simulation based on the Birming-
ham Rheumatoid Arthritis Model was adapted to the clinical practice patterns and
demographic characteristics of the patients and validated by clinical experts in
Colombia. The functional disability was assessed using the Health Assessment
Questionnaire (HAQ); the mean scores and the distribution were derived from sub-
jects screened to participate in clinical trials in Latin America. The effect of biologic
therapy was assessed using changes in HAQ scores for the first 6 months based on
a mixed treatment comparison and then projected over time. Direct medical costs
were calculated from private and public providers, and the information system of
the Ministry of Social Protection (SISMED). A 20-year time horizon and the payer’s
perspective were assumed. Costs and health outcomes were discounted at 3%
annually. Sensitivity analyses were performed to the main parameters of the
model. RESULTS:A hypothetical cohort of 1,000 patients with RA - IR MTX followed
for 20 years or until death, the mean direct medical costs per patient for abatacept
were U$132,654 (129,198-145,203), compared to U$283,753 (275,809-315,551) for to-
cilizumab. For the group of subjects treated with abatacept, 84% of these costs were
associated with the drug; for tocilizumab, 93% of the costs are associated with the
drug. The mean number of life years were 29.27 (28.45-30.15) and 29.25 (28.43-30.13)
for abatacept and tolicizumab respectively. The mean number of QALYs (dis-
counted) by abatacept, and tocilizumab were: 7.21 (7.02-7.42), and 7.15 (6.96-7.37)
respectively. Using abatacept as the reference treatment, tolicizumab provided less
utility at a higher cost, being dominated by abatacept. CONCLUSIONS: For the
treatment of RA in patients with IR MTX in Colombia, the use of abatacept, as the
reference treatment, is dominant over tocilizumab.
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OBJECTIVES: Fibromyalgia (FM) is a disease with a great economic impact not only
related to the costs associated but also to the loss of productivity. Effective treat-
ment options in the Mexican market are few. The objective of the present analysis
is to assess the cost-effectiveness of duloxetine in the treatment of patients with
FM versus pregabalin. METHODS: Alternatives to compare were: (1) duloxetine 60
mg / day and 120 mg / day and (2) pregabalin 300 mg / day and 450 mg / day. A
decision tree model was developed with a 12 weeks time horizon in which patients
maintained response, lost response or dropped out. Relative rates of response for
other comparators over placebo were extracted from a systematic review of pub-
lished randomized controlled studies for achieving a reduction of 30% in the Brief
Pain Inventory average pain severity score or a “much improved” or “very much
improved” rate in the Patient Global Impression of Improvement (PGI). Resource
use associated with fibromyalgia management was estimated from published
studies and costs were estimated from the Mexican Public Healthcare Payer per-
spective at 2010 USD prices. RESULTS: In the base case duloxetine 60 mg/day
versus the two indications of pregabalin were compared considering the price per
milligram for the 14 and 28 tablets of 75 mg presentations of pregabalin. In this
case, duloxetine is a dominant strategy versus pregabalin in 3 out of four scenarios
and highly cost-effective when compared duloxetine 120mg/day versus pregabalin
300mg/day. Further analysis (considering presentation 14/28 tablets of 150 mg of
pregabalin), shows that duloxetine is a highly cost-effective alternative with cost-
effectiveness ratios of $34-405 USD range per one additional response.
CONCLUSIONS: Results suggest duloxetine is a dominant and highly cost-effective
alternative compared with pregabalin at therapeutic doses published in studies of
comparable design in patients with FM.
PMS11
REVIEW OF THE STUDIES ON ECONOMIC EVALUATION OF TREATMENT FOR
POSTMENOPAUSAL OSTEOPOROSIS
Brandão CMR1, Acurcio FDA2
1Universidade Federal de Minas Gerais, Contagem, Minas Gerais, Brazil, 2Universidade Federal
de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
OBJECTIVES: The use of economic evaluation studies has been increasingly com-
mon, especially in the field of osteoporosis, in which there is wide a variation in
effectiveness and costs of therapeutic strategies. Aiming to identify relevant stud-
ies, there was a complete review of the economic evaluations, conducted in Brazil
and abroad, focusing on the treatment of postmenopausal osteoporosis to support
decision-making on health policies in Brazil and Latin America. METHODS: There
was a search on PubMed and the national scientific journals until February 2011.
We used the keywords {osteoporosis} and {postmenopausal or post-menopausal}
and {cost effectiveness or cost benefit or cost utility or Economic Evaluation}.
RESULTS: 147 titles and abstracts were found. After careful selection, 29 articles
remained for analysis. We found great variability in the methods of studies related
to the specific issues of each country (demographic and epidemiological factors),
associated with the perspective adopted, the prices, the valuation of health states
by population (utility) and according to factors inherent to economic modeling.
Most studies that compared treatment strategies with no treatment at all, found a
reasonable incremental cost-effectiveness ratio (ICER), according to the willing-
ness to pay of each country. The interventions have become more cost-effective
with increasing age, decreasing bone mineral density and the presence of previous
fractures. In general, bisphosphonates were the strategies that were evaluated the
most and they showed better results in ICER’s. Teriparatide was not cost-effective.
Studies evaluating hormone replacement therapy found good ICER, but call atten-
tion to the increased risk of breast cancer. Vitamin supplementation, strontium
ranelate, raloxifene, and denosumab were evaluated and showed variable results
depending on the perspective, of the country and the assumptions.
CONCLUSIONS: It was not possible to extrapolate any of the results to the popula-
tion of Brazil or countries of Latin America, limiting its use to decision makers in
yours different locations.
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OBJECTIVOS: Aproximadamente 30% de los pacientes con artritis reumatoide (AR)
tratados con inhibidores del factor de necrosis tumoral (anti-TNF) no alcanzan una
mejora de al menos 20% en los criterios del Colegio Americano de Reumatología
(ACR). El objetivo fue determinar la relación costo-utilidad de diferentes opciones
de tratamiento en pacientes con AR y falla a anti-TNF, desde la perspectiva del
sistema público de salud en México. METODOLOGÍAS: Se utilizó un modelo de
microsimulación (horizonte temporal de por vida) para comparar 12 diferentes
secuencias de tratamiento en un millón de pacientes (edad: 40 años, 70% mujeres,
peso corporal 66.67kg). En las secuencias, rituximab (2 infusiones de 1g por curso,
administrados cada 9 meses) podía ser utilizado inmediatamente tras la falla de un
anti-TFN (infliximab, etanercept o adalimumab) o hasta después de agotar los 3
anti-TNF. Mediante una comparación indirecta de 23 ensayos clínicos, se deter-
minaron las respuestas ACR ajustadas para cada agente. Un panel integrado por
diez expertos y literatura publicada sirvió para determinar el consumo de recursos.
Se consultaron costos unitarios oficiales. Analizamos los costos de adquisición e
infusión de medicamentos (incluyendo metotrexato), el costo ambulatorio por re-
spuesta ACR y el costo hospitalario según puntaje HAQ (Health Assessment
Questionnaire). RESULTADOS: Los costos acumulados de por vida (descontados a
una tasa anual de 3%) fueron más bajos para todas las secuencias en las que
rituximab fue administrado como primera opción ante una respuesta insuficiente
al tratamiento con un anti-TNF. Los ahorros oscilaron entre $6904 y $16,411 pesos
mexicanos por paciente. Las mayores diferencias en calidad de vida a favor de
iniciar con rituximab se obtuvieron cuando se comparó contra iniciar con
infliximab. CONCLUSIONES: Este estudio sugiere que iniciar terapia con rituximab
inmediatamente después de la primer falla a anti-TNF es una estrategia costo-
efectiva en lugar de continuar con otro agente anti-TFN.
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OBJECTIVES: To estimate employer productivity offset costs when using Tumor
Necrosis Factor inhibitors (TNF-i) therapies for treatment of Rheumatoid Arthritis
(RA) using an economic model that encompasses a broad set of workplace costs
from RA.METHODS:A customizable model of the workplace impacts of alternative
RA treatments was calibrated with Brazilian specific parameters based on data
from literature, clinical trials, and government sources. The workplace model in-
cluded employment sector wages to allow for comparisons across industries. Costs
of medical leave absenteeism/disability, reduced productivity, job turnover, and
work-equipment adaptations were calculated for RA employees on the TNF-i ver-
sus other traditional DMARDs RA treatments. Employer costs of RA workers on
TNF-i versus traditional DMARDs were compared. RESULTS: Across all industries
in Brazil, the annual workplace cost of employees with RA was R$4,839 for employ-
ees on adalimumab (23% of wages) versus R$8,679 for employees on traditional
DMARDs therapies (42% of wages). The R$3,839 offset reduction in employer costs
for RA workers on adalimumab included reduced medical leave (R$764) and RA-
related job turnover (R$1,076), and higher productivity (R$1,999). Savings per RA
worker on adalimumab ranged from R$2,597 (19% of wages) in the waste treatment
sector to R$26,312 (19% of wages) in the petroleum product manufacturing sector.
CONCLUSIONS: RA imposes a large financial burden on employers in Brazil. This
burden is substantially less for employees treated with adalimumab than for em-
ployees treated with traditional DMARDs as a result of the higher productivity,
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